Oncogenic driver mutations, treatment, and EGFR-TKI resistance in a Caucasian population with non-small cell lung cancer: survival in clinical practice.

Oncotarget · 2017 · PMC5652823 · PMID 29100434

Europe PMC DOI

hedged sentence

0.0015

closest p · 0.0× alpha

0.0015

boldest claim

The sentences

highly significantp=0.0015actually significant

Case-control analysis by stage revealed no difference in OS in stage I-III patients but a highly significant benefit in OS in the stage IV driver-positive population (HR 0.39, CI 0.18 - 0.61, p=0.0015 [Figure 2C, 2D ]).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.